The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Oral azacitidine plus R-CHOP for previously untreated NHL
John Leonard, MD, from Weill Cornell Medical College, New York City, NY, discusses the Phase I CC-486-DLBCL-001 study (NCT02343536) investigating oral azacitidine, a DNA methyltransferase inhibitor, plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma (DLBCL), grade 3B follicular lymphoma (FL), or transformed lymphoma. Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Leonard reveals that oral azacitidine prior to R-CHOP demonstrated promising clinical activity in all three disease groups, with the results supporting further investigation of this combination.
